Nordic Innovation Fair

Stockholm’s life science ecosystem has long shone brightly for its scientific excellence. Now, the region is tackling how to turn its world-class research, strong infrastructure, and an industrial legacy into sustained global competitiveness.

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the European Union for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer — the first new regimen in more than ten years for this patient group.

The company has completed the eight-week treatment period for all patients in its pivotal Phase III HEEALING1 study of linaprazan glurate in erosive gastroesophageal reflux disease (GERD), with topline results now expected in the fourth quarter of 2026.

Europe has the science. What it doesn't have is the capital, and industry leaders warn that gap is pushing the region's most promising biotechs to scale up in the US instead.

The story of Finnish biotechnology is not a straightforward success story. It is a story of an ambitious start, of setbacks, and of stubborn rebuilding – and of what happens when a field that demands patience meets short-term expectations. As Finnish Bioindustries turns 20, it is a good moment to look back.

Elicera Therapeutics has received a Notice of Allowance from the Japan Patent Office (JPO) for its patent application covering the oncolytic virus candidate ELC-201 in solid tumors.

Uppsala-based Readily Diagnostics has received a grant of approximately USD 970,000 (about SEK 9 million) from the Gates Foundation to develop a low-cost point-of-care test for chlamydia, gonorrhea and trichomoniasis, aimed at low-resource settings.